The MAPK (mitogen-activated protein kinase) kinase (MEK1/2) signal transduction cascade plays a central role in the regulation of many cellular processes. Selumetinib (AZD6244, ARRY-142886), a selective non-ATP competitive small-molecule inhibitor of MEK1/2,1 has been used …
No takes yet. Share an insight, caveat, or question.
Chen et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: